Although in this study, we have demonstrated that autologous bone marrow leukocytes can efficiently be packed with an oncolytic virus like MYXV, resulting in therapeutic effects against drug resistant MM cells, future studies should be focused on understanding the mechanisms by which oncolytic virotherapy with MYXV alone or in combination with chemotherapeutic/immunotheraputic agents results in cancer-free or cancer-controlling outcomes in the pre-clinical murine Vk*MYC model. Here, MYC is linked to cancer.